Komplementäre Behandlungsverfahren bei kindlichen Kopfschmerzen

Zusammenfassung

Gegenstand und Ziel: Komplementäre und alternative Behandlungsverfahren (CAM) werden bei primären Kopfschmerzen vielfach angewendet. Ziel dieser Arbeit ist es, die Evidenzlage dieser Methoden bei kindlichen Kopfschmerzen darzustellen. Methoden: Es wurden medizinische Datenbanken (Medline, Cochrane Bibliothek) nach Studien über CAM bei Kindern mit Kopfschmerzen durchforstet. Dabei wurden Artikel der letzten 20 Jahre berücksichtigt. Ergebnisse: Obwohl komplementäre und alternative Therapien eine wachsende Rolle in der multidisziplinären Behandlung von Kopfschmerzen im Kindesund Jugendalter spielen, sind bislang kaum hochwertige klinische Studien zu verzeichnen. Lediglich für die Akupunktur als Methode gibt es einen gewissen Grad an Evidenz hinsichtlich ihrer Wirksamkeit für eine mögliche Kopfschmerzprophylaxe bei Kindern. Schlussfolgerung: Es gibt immer noch wenig Evidenz bezüglich der Wirksamkeit unterschiedlicher komplementärer Behandlungsmethoden bei kindlichen Kopfschmerzen. Randomisierte klinische Studien mit hinreichenden Fallzahlen wären hier dringend wünschenswert.

Summary:

Objective: Complementary and alternative medicine (CAM) is widely used in patients with primary headache syndromes. The aim of this review is to give an overview of the current evidence concerning CAM use in children with headache. Methods: Medline and Cochrane library were systematically searched for articles dealing with CAM in children with headache taking into account articles published within the past 20 years. Results: Despite increasing CAM use in the multidisciplinary treatment of headache in children and adolescents, only very few clinical trials of higher quality exist. Only in acupuncture a certain level of evidence concerning efficacy for headache prophylaxis in children exists. Conclusion: There is still limited evidence concerning efficacy of CAM methods in children with headache. Randomised controlled trials with adequate numbers of cases are highly warranted.

Schlüsselwörter

Komplementäre und alternative Behandlungsmethoden - Kopfschmerzen - Kinder - Akupunktur

Keywords

Complementary and alternative medicine (CAM) - headache in children - acupuncture

• Literatur

• 1 Ottolini MC. et al. Complementary and alternative medicine use among children in the Washington, DC area. Ambul Pediatr 2001; 01: 122-5.
• 2 Smith C, Eckert K. Prevalence of complementary and alternative medicine and use among children in South Australia. Journal of paediatrics and child health 2006; 42: 538-543.
• 3 Shenfield G, Lim E, Allen H. Survey of the use of complementary medicines and therapies in children with asthma. Journal of paediatrics and child health 2002; 38: 252-257.
• 4 Gaul C. et al. Use of complementary and alternative medicine in patients suffering from primary headache disorders. Cephalalgia 2009; 29: 1069-78.
• 5 Weissenstein A. et al. High Frequency of CAM Use Among Children in Germany. J Altern Complement Med 2012; 18: 729-730.
• 6 Eisenberg DM. et al. Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 1998; 280: 1569-75.
• 7 Häußermann D. Allensbach-Studie: Wachsendes Vertrauen in Naturheilmittel. Deutsches Ärzteblatt 1997; 94: A2466-A2467.
• 8 Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States – prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246-252.
• 9 Termine C, Ozge A, Antonaci F, Natriashvili S, Guidetti V, Wober-Bingol C. Overview of diagnosis and management of paediatric headache. Part II: therapeutic management. The journal of headache and pain 2011; 12: 25-34.
• 10 Cheng X. Chinese acupuncture and moxibustion. Beijing: Foreign Languages Press; 2 1987
• 11 Bodeker G, Ong C, Grundy C, Burford G, Shein K. WHO Global Atlas of Traditional, Complementary and Alternative Medicine. Kobe: WHO Center for Health Development; 2005
• 12 Pintov S, Lahat E, Alstein M, Vogel Z, Barg J. Acupuncture and the opioid system: implications in management of migraine. Pediatric neurology 1997; 17: 129-133.
• 13 Gottschling S. et al. Laser acupuncture in children with headache: a double-blind, randomized, bicenter, placebo-controlled trial. Pain 2008; 137: 405-12.
• 14 Linde K. et al. Acupuncture for migraine prophylaxis. Cochrane Database Syst Rev. 2009 DOI: 10.1002/14651858.CD001218.pub2: CD001218.
• 15 Linde K. et al. Acupuncture for tension-type headache. Cochrane Database Syst Rev 2009. DOI: 10.1002/14651858.CD007587: CD007587.
• 16 Melchart D. et al. Acupuncture versus placebo versus sumatriptan for early treatment of migraine attacks: a randomized controlled trial. Journal of internal medicine 2003; 253: 181-188.
• 17 Vickers AJ. et al. Acupuncture for chronic pain: individual patient data meta-analysis. Arch Intern Med 2012; 172: 1444-53.
• 18 Gottschling S. et al. Use of complementary and alternative medicine in healthy children and children with chronic medical conditions in Germany. Complement Ther Med 2013; 21 (Suppl. 01) S61-9.
• 19 Danno K, Colas A, Masson JL, Bordet MF. Homeopathic treatment of migraine in children: results of a prospective, multicenter, observational study. J Altern Complement Med 2013; 19: 119-23.
• 20 Muscari-Tomaioli G. et al. Observational study of quality of life in patients with headache, receiving homeopathic treatment. Br Homeopath J 2001; 90: 189-97.
• 21 Witt CM, Ludtke R, Willich SN. Homeopathic treatment of patients with migraine: a prospective observational study with a 2-year follow-up period. J Altern Complement Med 2010; 16: 347-355.
• 22 Walach H. et al. Classical homeopathic treatment of chronic headaches. Cephalalgia 1997; 17: 119-26.
• 23 Whitmarsh TE, Coleston-Shields DM, Steiner TJ. Double-blind randomized placebo-controlled study of homoeopathic prophylaxis of migraine. Cephalalgia 1997; 17: 600-604.
• 24 Straumsheim P, Borchgrevink C, Mowinckel P, Kierulf H, Hafslund O. Homeopathic treatment of migraine: a double blind, placebo controlled trial of 68 patients. The British homoeopathic journal 2000; 89: 4-7.
• 25 Walach H. et al. The long-term effects of homeopathic treatment of chronic headaches: one year follow-up and single case time series analysis. Br Homeopath J 2001; 90: 63-72.
• 26 Wang F. et al. Oral Magnesium oxide prophylaxis of frequent migrainous headache in children. A randomized, double-blind, placebo-controlled trial. Headache 2003; 43: 601-610.
• 27 Mauskop A, Altura BT, Altura BM. Serum ionized magnesium levels and serum ionized calcium/ionized magnesium ratios in women with menstrual migraine. Headache 2002; 42: 242-248.
• 28 Facchinetti F, Sances G, Borella P, Genazzani AR, Nappi G. Magnesium prophylaxis of menstrual migraine: effects on intracellular magnesium. Headache 1991; 31: 298-301.
• 29 Peikert A, Wilimzig C, Kohne-Volland R. Prophylaxis of migraine with oral magnesium: results from a prospective, multi-center, placebo-controlled and double-blind randomized study. Cephalalgia 1996; 16: 257-263.
• 30 Koseoglu E, Talaslioglu A, Gonul AS, Kula M. The effects of magnesium prophylaxis in migraine without aura. Magnesium research 2008; 21: 101-108.
• 31 Cete Y. et al. A randomized prospective placebocontrolled study of intravenous magnesium sulphate vs. metoclopramide in the management of acute migraine attacks in the Emergency Department. Cephalalgia 2005; 25: 199-204.
• 32 Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulphate relieves migraine attacks in patients with low serum ionized magnesium levels: a pilot study. Clin Sci 1995; 89: 633-6.
• 33 Mauskop A, Altura BT, Cracco RQ, Altura BM. Intravenous magnesium sulfate rapidly alleviates headaches of various types. Headache 1996; 36: 154-60.
• 34 Koo B. et al. Mitochondrial encephalomyopathy, lactic acidosis, stroke-like episodes (MELAS): clinical, radiological, pathological, and genetic observations. Ann Neurol 1993; 34: 25-32.
• 35 Lanteri-Minet M, Desnuelle C. [Migraine and mitochondrial dysfunction]. Revue neurologique 1996; 152: 234-238.
• 36 Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998; 50: 466-470.
• 37 MacLennan SC, Wade FM, Forrest KM, Ratanayake PD, Fagan E, Antony J. High-dose riboflavin for migraine prophylaxis in children: a doubleblind, randomized, placebo-controlled trial. Journal of child neurology 2008; 23: 1300-1304.
• 38 Bruijn J. et al. Medium-dose riboflavin as a prophylactic agent in children with migraine: a preliminary placebo-controlled, randomised, doubleblind, cross-over trial. Cephalalgia 2010; 30: 1426-1434.
• 39 Condo M, Posar A, Arbizzani A, Parmeggiani A. Riboflavin prophylaxis in pediatric and adolescent migraine. J Headache Pain 2009; 10: 361-365.
• 40 Hershey AD. et al. Coenzyme Q10 deficiency and response to supplementation in pediatric and adolescent migraine. Headache 2007; 47: 73-80.
• 41 Slater SK, Nelson TD, Kabbouche MA, LeCates SL, Horn P, Segers A, Manning P, Powers SW, Hershey AD. A randomized, double-blinded, placebo-controlled, crossover, add-on study of CoEnzyme Q10 in the prevention of pediatric and adolescent migraine. Cephalalgia 2011; 31: 897-905.
• 42 Gaul C, Diener HC, Danesch U. bon behalf of the Migravent® Study Group. Improvement of migraine symptoms with aproprietary supplement containing riboflavin, magnesium and Q10: a randomized, placebo-controlled, double-blind, multicenter trial). The Journal of Headache and Pain 2015; 16: 32.
• 43 Eaton J. Butterbur, herbal help for migraine. Nat Pharm 1998; 02: 23-24.
• 44 Oelkers-Ax R, Leins A, Parzer P, Hillecke T, Bolay HV, Fischer J, Bender S, Hermanns U, Resch F. Butterbur root extract and music therapy in the prevention of childhood migraine: an explorative study. Eur J Pain 2008; 12: 301-13.
• 45 Pothmann R, Danesch U. Migraine prevention in children and adolescents: results of an open study with a special butterbur root extract. Headache 2005; 45: 196-203.
• 46 Heptinstall S, White A, Williamson L, Mitchell JR. Extracts of feverfew inhibit granule secretion in blood platelets and polymorphonuclear leucocytes. Lancet 1985; 01: 1071-1074.
• 47 Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behaviour via neutralization of sulphydryl groups. The Journal of pharmacy and pharmacology 1987; 39: 459-465.
• 48 Pugh WJ, Sambo K. Prostaglandin synthetase inhibitors in feverfew. The Journal of pharmacy and pharmacology 1988; 40: 743-745.
• 49 Makheja AN, Bailey JM. A platelet phospholipase inhibitor from the medicinal herb feverfew (Tanacetum parthenium). Prostaglandins, leukotrienes, and medicine 1982; 08: 653-660.
• 50 Draves A, Walker S. Parthenolide content of Canadian commercial feverfew preparations: Label claims are misleading in most cases. Can Pharm J (RPC) 2003; 136: 23-30.
• 51 Willigmann I, Freudenstein J. Production of a Stable Feverfew (Tanacetum Parthenium) Extract as an Active Substance for a Pharmaceutical Product. 1998; Vienna: Society for Medicinal Plant Research; 1998
• 52 Diener HC. et al. Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention – a randomized, double-blind, multicentre, placebo-controlled study. Cephalalgia 2005; 25: 1031-1041.
• 53 Esposito M, Ruberto M, Pascotto A, Carotenuto M. Nutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behaviour. Neurol Sci 2012; 33: 1365-1368.
• 54 Beyer WF. Kopfschmerz – was ist osteopathische Medizin?. Manuelle Medizin 2001; 39: 301-303.
• 55 Borusiak P, Biedermann H, Bosserhoff S, Opp J. Lack of efficacy of manual therapy in children and adolescents with suspected cervicogenic headache: results of a prospective, randomized, placebo-controlled, and blinded trial. Headache 2010; 50: 224-230.